Your email has been successfully added to our mailing list.

×
0 0.011093502377179 0.011093502377179 0.011093502377179 0.011093502377179 0.00158478605388269 -0.00158478605388283 -0.00158478605388283
Stock impact report

Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

Calithera Biosciences, Inc. (CALA) 
Last calithera biosciences, inc. earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
Company Research Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that an abstract describing a Phase 2 study of telaglenastat, the company’s glutaminase inhibitor, will be presented at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Annual Meeting. The KEAPSAKE study (NCT04265534) will explore telaglenastat versus placebo in combination with a standard-of-care regimen of immunotherapy and chemotherapy as first-line treatment for patients with non-small cell lung cancers (NSCLC) with KEAP1/NRF2 mutations. These mutations, which occur in an estimated 20 percent of NSCLC patients, are associated with aggressive tumor growth and poor outcomes to standard-of-care therapy. Title: A phase II randomized study of telaglenastat, a glutaminase inhi Show less Read more
Impact Snapshot
Event Time:
CALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CALA alerts
Opt-in for
CALA alerts

from News Quantified
Opt-in for
CALA alerts

from News Quantified